CY1119521T1 - Συνθεσεις και μεθοδοι για την καταστολη ενδομητρικου πολλαπλασιασμου - Google Patents
Συνθεσεις και μεθοδοι για την καταστολη ενδομητρικου πολλαπλασιασμουInfo
- Publication number
- CY1119521T1 CY1119521T1 CY20171101111T CY171101111T CY1119521T1 CY 1119521 T1 CY1119521 T1 CY 1119521T1 CY 20171101111 T CY20171101111 T CY 20171101111T CY 171101111 T CY171101111 T CY 171101111T CY 1119521 T1 CY1119521 T1 CY 1119521T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- present
- relates
- compositions
- estrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title 1
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 239000003607 modifier Substances 0.000 abstract 2
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 102100025803 Progesterone receptor Human genes 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 201000006828 endometrial hyperplasia Diseases 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 239000000044 progesterone antagonist Substances 0.000 abstract 1
- 108090000468 progesterone receptors Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86263206P | 2006-10-24 | 2006-10-24 | |
| US88534807P | 2007-01-17 | 2007-01-17 | |
| PCT/US2007/082432 WO2008067086A2 (en) | 2006-10-24 | 2007-10-24 | Compositions and methods for suppressing endometrial proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119521T1 true CY1119521T1 (el) | 2018-03-07 |
Family
ID=39468586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101111T CY1119521T1 (el) | 2006-10-24 | 2017-10-25 | Συνθεσεις και μεθοδοι για την καταστολη ενδομητρικου πολλαπλασιασμου |
| CY20201100748T CY1123239T1 (el) | 2006-10-24 | 2020-08-12 | Συνθεσεις και μεθοδοι για καταστολη ενδομητριωνυπερπλασιων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100748T CY1123239T1 (el) | 2006-10-24 | 2020-08-12 | Συνθεσεις και μεθοδοι για καταστολη ενδομητριωνυπερπλασιων |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9283234B2 (enExample) |
| EP (3) | EP2078032B1 (enExample) |
| JP (5) | JP2010507685A (enExample) |
| KR (1) | KR20090067198A (enExample) |
| AU (1) | AU2007327707B2 (enExample) |
| BR (1) | BRPI0717747A2 (enExample) |
| CA (1) | CA2673128C (enExample) |
| CR (1) | CR10826A (enExample) |
| CY (2) | CY1119521T1 (enExample) |
| DK (2) | DK2078032T3 (enExample) |
| EA (1) | EA017227B1 (enExample) |
| EC (1) | ECSP099349A (enExample) |
| ES (2) | ES2814343T3 (enExample) |
| HK (1) | HK1216849A1 (enExample) |
| HU (2) | HUE036870T2 (enExample) |
| IL (2) | IL197893A (enExample) |
| LT (2) | LT3263112T (enExample) |
| MX (2) | MX2009003953A (enExample) |
| MY (1) | MY150763A (enExample) |
| NO (1) | NO342085B1 (enExample) |
| NZ (1) | NZ576274A (enExample) |
| PL (2) | PL2078032T3 (enExample) |
| PT (2) | PT2078032T (enExample) |
| SI (2) | SI2078032T1 (enExample) |
| WO (1) | WO2008067086A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5193196B2 (ja) | 2006-06-02 | 2013-05-08 | ペア ツリー ウーマンズ ヘルス ケア | 萎縮性膣炎の治療の方法 |
| EP2078032B1 (en) * | 2006-10-24 | 2017-08-02 | Repros Therapeutics Inc. | Compositions and methods for suppressing endometrial proliferation |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TW201002736A (en) * | 2008-04-28 | 2010-01-16 | Repros Therapeutics Inc | Compositions and methods for treating progesterone-dependent conditions |
| RU2373977C1 (ru) * | 2008-08-05 | 2009-11-27 | Государственное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" | Способ лечения болевого синдрома при викарном увеличении яичника после односторонней аднексэктомии |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
| SG10201704858PA (en) | 2012-05-31 | 2017-07-28 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
| EP2914268B1 (en) | 2012-11-02 | 2018-07-04 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| FR2997628B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
| JP2016516764A (ja) | 2013-04-10 | 2016-06-09 | プレグレム ソシエテ アノニム | 子宮筋腫治療に用いるプロゲステロン受容体調節剤 |
| US20190008804A1 (en) * | 2016-01-12 | 2019-01-10 | Repros Therapeutics Inc. | Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4038389A (en) * | 1975-05-07 | 1977-07-26 | The Upjohn Company | Medroxyprogesterone acetate compositions |
| US4409208A (en) | 1980-04-15 | 1983-10-11 | The Salk Institute For Biological Studies | GnRH antagonists |
| ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| US4619914A (en) | 1983-03-10 | 1986-10-28 | The Salk Institute For Biological Studies | GNRH antagonists IIIB |
| US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
| US4547370A (en) | 1983-11-29 | 1985-10-15 | The Salk Institute For Biological Studies | GnRH Antagonists |
| DE3347126A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4569927A (en) | 1984-02-23 | 1986-02-11 | The Salk Institute For Biological Studies | GnRH Antagonists IV |
| US4565804A (en) | 1984-09-07 | 1986-01-21 | The Salk Institute For Biological Studies | GnRH Antagonists VI |
| DE3506785A1 (de) | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5446178A (en) | 1987-03-18 | 1995-08-29 | Schering Aktiengesellschaft | Process for preparing 19,11β-bridged steroids |
| DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3866410D1 (de) | 1987-04-24 | 1992-01-09 | Akzo Nv | 11-arylestranderivate und 11-arylpregnanderivate. |
| ATE85342T1 (de) | 1987-12-12 | 1993-02-15 | Akzo Nv | 11-arylsteroid-derivate. |
| DE3820948A1 (de) | 1988-06-16 | 1989-12-21 | Schering Ag | 10ss, 11ss-ueberbrueckte steroide |
| DE3822770A1 (de) | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
| DE3832303A1 (de) | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
| DE3917274A1 (de) | 1989-05-24 | 1990-11-29 | Schering Ag | 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3921059A1 (de) | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| DE4042007A1 (de) | 1990-12-22 | 1992-06-25 | Schering Ag | 6,7-modifizierte-11(beta)-aryl-4-estrene |
| US5407928A (en) | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
| DE4038128A1 (de) | 1990-11-27 | 1992-06-04 | Schering Ag | 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| ZA929315B (en) | 1991-12-20 | 1993-05-24 | Akzo Nv | 17-spirofuran-3'-ylidene steroids. |
| DE4216003A1 (de) | 1992-05-12 | 1993-11-18 | Schering Ag | Dissoziierte kompetitive Progesteronantagonisten |
| US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| DE4216004B4 (de) | 1992-05-12 | 2008-03-27 | Bayer Schering Pharma Akiengesellschaft | Verwendung kompetitiver Progesteronantagonisten |
| ATE209189T1 (de) | 1992-07-01 | 2001-12-15 | Ortho Pharma Corp | 1-arylsulfonyl-3-phenyl-1,4,5,6- tetrahydropyridazinen |
| US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| DE4434488A1 (de) | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5576310A (en) | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
| US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1997041145A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| US5753655A (en) | 1996-10-10 | 1998-05-19 | Ortho Pharmaceutical Corporation | 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation |
| DE19652408C2 (de) | 1996-12-06 | 2002-04-18 | Schering Ag | Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| DE19809845A1 (de) | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6689768B2 (en) * | 1998-04-15 | 2004-02-10 | Jenapharm Gmbh & Co. Kg | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| SE514556C2 (sv) | 1999-07-09 | 2001-03-12 | Jema Jori Ab | Metod för hantering av en databas |
| AU775831B2 (en) | 1999-12-29 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates |
| US7109171B2 (en) * | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| DK1265911T3 (da) * | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
| KR101229701B1 (ko) * | 2004-07-09 | 2013-02-05 | 라보라토이레 에이치알에이 파르마 | 프로게스테론 수용체 조절제를 함유하는 서방형 조성물 |
| EP2078032B1 (en) * | 2006-10-24 | 2017-08-02 | Repros Therapeutics Inc. | Compositions and methods for suppressing endometrial proliferation |
-
2007
- 2007-10-24 EP EP07871232.0A patent/EP2078032B1/en active Active
- 2007-10-24 MX MX2009003953A patent/MX2009003953A/es active IP Right Grant
- 2007-10-24 KR KR1020097009508A patent/KR20090067198A/ko not_active Ceased
- 2007-10-24 CA CA2673128A patent/CA2673128C/en not_active Expired - Fee Related
- 2007-10-24 DK DK07871232.0T patent/DK2078032T3/da active
- 2007-10-24 MY MYPI20091368 patent/MY150763A/en unknown
- 2007-10-24 PL PL07871232T patent/PL2078032T3/pl unknown
- 2007-10-24 EP EP20167723.4A patent/EP3693376A1/en not_active Withdrawn
- 2007-10-24 EP EP17184128.1A patent/EP3263112B1/en not_active Not-in-force
- 2007-10-24 LT LTEP17184128.1T patent/LT3263112T/lt unknown
- 2007-10-24 NZ NZ576274A patent/NZ576274A/en not_active IP Right Cessation
- 2007-10-24 DK DK17184128.1T patent/DK3263112T3/da active
- 2007-10-24 PT PT78712320T patent/PT2078032T/pt unknown
- 2007-10-24 HU HUE07871232A patent/HUE036870T2/hu unknown
- 2007-10-24 WO PCT/US2007/082432 patent/WO2008067086A2/en not_active Ceased
- 2007-10-24 PT PT171841281T patent/PT3263112T/pt unknown
- 2007-10-24 LT LTEP07871232.0T patent/LT2078032T/lt unknown
- 2007-10-24 SI SI200731976T patent/SI2078032T1/sl unknown
- 2007-10-24 JP JP2009534845A patent/JP2010507685A/ja active Pending
- 2007-10-24 US US12/446,567 patent/US9283234B2/en not_active Expired - Fee Related
- 2007-10-24 ES ES17184128T patent/ES2814343T3/es active Active
- 2007-10-24 AU AU2007327707A patent/AU2007327707B2/en not_active Ceased
- 2007-10-24 EA EA200970409A patent/EA017227B1/ru unknown
- 2007-10-24 MX MX2013010762A patent/MX343130B/es unknown
- 2007-10-24 SI SI200732158T patent/SI3263112T1/sl unknown
- 2007-10-24 BR BRPI0717747-0A2A patent/BRPI0717747A2/pt not_active IP Right Cessation
- 2007-10-24 HU HUE17184128A patent/HUE051484T2/hu unknown
- 2007-10-24 PL PL17184128T patent/PL3263112T3/pl unknown
- 2007-10-24 ES ES07871232.0T patent/ES2643318T3/es active Active
-
2009
- 2009-04-05 IL IL197893A patent/IL197893A/en active IP Right Grant
- 2009-05-20 NO NO20091966A patent/NO342085B1/no not_active IP Right Cessation
- 2009-05-20 EC EC2009009349A patent/ECSP099349A/es unknown
- 2009-05-22 CR CR10826A patent/CR10826A/es unknown
-
2013
- 2013-12-16 JP JP2013259154A patent/JP6175364B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-11 US US14/251,192 patent/US9616074B2/en not_active Expired - Fee Related
-
2015
- 2015-05-14 IL IL238823A patent/IL238823B/en active IP Right Grant
-
2016
- 2016-04-27 HK HK16104781.7A patent/HK1216849A1/zh unknown
- 2016-07-27 JP JP2016147279A patent/JP2016183199A/ja active Pending
-
2017
- 2017-03-21 US US15/464,736 patent/US20170189421A1/en not_active Abandoned
- 2017-08-28 JP JP2017163450A patent/JP2017203049A/ja active Pending
- 2017-10-25 CY CY20171101111T patent/CY1119521T1/el unknown
-
2019
- 2019-04-03 JP JP2019071622A patent/JP2019131587A/ja active Pending
-
2020
- 2020-08-12 CY CY20201100748T patent/CY1123239T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119521T1 (el) | Συνθεσεις και μεθοδοι για την καταστολη ενδομητρικου πολλαπλασιασμου | |
| IL258880A (en) | Diarylhydantoin compounds | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| NO20084480L (no) | Diaryltiohydantoin forbindelser | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| EA201300116A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| EA201290356A1 (ru) | Композиции для лечения тошноты и рвоты центрального происхождения | |
| CY1107816T1 (el) | Η χρηση ενος συνδυασμου ενος αναστολεα αρωματασης, μιας προγεστερονης και ενος οιστρογονου για τη θεραπεια της ενδομητριωσης | |
| NO20065297L (no) | Anvendelse av GPCR54 ligander til behandling av infertilitet | |
| DE602006005084D1 (de) | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen | |
| ATE445408T1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie | |
| CY1116592T1 (el) | ΣΥΝΔΥΑΣΤΙΚΗ ΘΕΡΑΠΕΙΑ ΠΟΥ ΕΜΠΕΡΙΕΧΕΙ ΑΝΤΑΓΩΝΙΣΤΕΣ α5β1 | |
| CY1116786T1 (el) | Συνθεσεις και μεθοδοι για διαγνωση και θεραπεια του καρκινου |